Investment Opportunity
Join the $4.45B Mobile Wound Care Revolution
Medipyxis is building the vertical SaaS operating system for mobile wound care — a large, high-growth specialty with no dominant software platform. We're early, we're moving fast, and the market timing is right.
$4.45B*
Mobile wound care market
Medipyxis internal market analysis
7-to-1
Tool consolidation
single platform replaces 7+ point tools
Recovered referrals*
Common early outcome
observed in first 90 days for representative customers
>65M
Chronic wound patients
in the United States
The Investment Thesis
Six reasons Medipyxis is positioned to become the category-defining platform for mobile wound care.
A Large, Underserved Market
Mobile wound care is a $4.45 billion specialty with no dominant vertical software platform. The market runs on general EMRs, spreadsheets, and point-solution tools that were never designed for mobile, field-based care. The fragmentation creates opportunity for a purpose-built platform.
Vertical SaaS With High Retention
When a practice adopts Medipyxis, the platform becomes the operating system for the entire clinical and business workflow. Patient records, billing history, graft inventory, and compliance data all live inside. Switching costs are high. Net revenue retention is structurally strong.
Multiple Revenue Vectors
Medipyxis generates subscription revenue from clinical practices, transaction-based revenue from billing and revenue cycle services, and vendor portal access fees from graft and tissue vendors. As the platform scales, each vector compounds.
Regulatory Tailwinds
Medicare LCD requirements for wound care documentation are tightening. Audit rates are rising. Practices that are not using compliant, audit-ready documentation systems are increasingly at risk. Medipyxis is the compliance solution — not an optional upgrade.
Network Effects in the Supply Chain
When graft vendors connect their consignment inventory to Medipyxis, their product data flows directly into clinical workflows. As more vendors join, the platform becomes the de facto supply chain layer for mobile wound care — creating a two-sided network with defensible positions on both sides.
Early Traction, Right Timing
The mobile wound care market is consolidating. Independent practices are growing. Reimbursement reform is driving more wound care into the mobile setting. Medipyxis is positioned to become the category leader before larger incumbents prioritize this specialty.
Why Now
Healthcare reimbursement continues to shift care from expensive hospital and clinic settings into the community — SNFs, ALFs, and patient homes. Mobile wound care is a direct beneficiary of that shift. As the patient population grows and the regulatory environment tightens, practices that operate on outdated tool stacks will consolidate or fail.
Medipyxis is the platform those practices will run on. We're raising capital now to accelerate product development, expand the sales team, and establish category leadership before larger EMR incumbents prioritize this specialty.
Download the Pitch Deck
Fill out the form below to access the full investor deck. Your download will begin immediately after submission.
Investment Highlights
- Large, underserved mobile wound care market with no dominant vertical software platform*
- Tool consolidation thesis — single platform designed to replace 7+ point tools
- Multiple revenue vectors: SaaS subscription, RCM transactions, and vendor portal fees
- Regulatory tailwinds: tightening LCD documentation requirements drive urgency
- Designed for network effects as graft vendors connect to the supply chain layer
- Recovered-referrals outcomes observed in early customers within the first 90 days*
- Early-stage — positioned to pursue category leadership in the specialty
Important Disclosures
Forward-looking statements. This page contains forward-looking statements regarding market opportunity, growth strategy, competitive positioning, and product roadmap. These statements reflect management’s current expectations and assumptions and are subject to known and unknown risks and uncertainties — including but not limited to market adoption, regulatory change, competitive dynamics, reimbursement policy, execution risk, and capital availability — that could cause actual results to differ materially. Past or anecdotal outcomes are not indicative of future results. Investors should conduct their own due diligence and should not rely solely on the information presented here.
*Market figures.Market-size figures (e.g., “$4.45B”) reflect Medipyxis’s internal market analysis built from publicly available sources. Methodology and source list are available on request through the investor contact below.
*Customer outcomes. Outcome examples (revenue recovered, denial rates, documentation time) reflect representative early customers using Medipyxis workflows as designed. Outcomes vary by customer baseline, adoption depth, and implementation quality, and are not a guarantee of comparable results for any other customer.
Offer scope. This page is informational only and does not constitute an offer to sell or a solicitation of an offer to buy any securities. Any future offering will be conducted pursuant to applicable exemptions and made only through formal offering materials provided to qualified investors.
Interested in Investing?
We're selective about our investor partners and value strategic alignment with our mission. If you're interested in learning more, reach out directly.